TY - JOUR
T1 - Multiplex assays for biomarker research and clinical application
T2 - Translational science coming of age
AU - Fu, Qin
AU - Schoenhoff, Florian S.
AU - Savage, William J.
AU - Zhang, Pingbo
AU - van Eyk, Jennifer E.
PY - 2010/3
Y1 - 2010/3
N2 - Over the last decade, translational science has come into the focus of academic medicine, and significant intellectual and financial efforts have been made to initiate a multitude of benchto-bedside projects. The quest for suitable biomarkers that will significantly change clinical practice has become one of the biggest challenges in translational medicine. Quantitative measurement of proteins is a critical step in biomarker discovery. Assessing a large number of potential protein biomarkers in a statistically significant number of samples and controls still constitutes a major technical hurdle. Multiplexed analysis offers significant advantages regarding time, reagent cost, sample requirements and the amount of data that can be generated. The two contemporary approaches in multiplexed and quantitative biomarker validation, antibody-based immunoassays and MS-based multiple (or selected) reaction monitoring, are based on different assay principles and instrument requirements. Both approaches have their own advantages and disadvantages and therefore have complementary roles in the multi-staged biomarker verification and validation process. In this review, we discuss quantitative immunoassay and multiple reaction monitoring/selected reaction monitoring assay principles and development. We also discuss choosing an appropriate platform, judging the performance of assays, obtaining reliable, quantitative results for translational research and clinical applications in the biomarker field.
AB - Over the last decade, translational science has come into the focus of academic medicine, and significant intellectual and financial efforts have been made to initiate a multitude of benchto-bedside projects. The quest for suitable biomarkers that will significantly change clinical practice has become one of the biggest challenges in translational medicine. Quantitative measurement of proteins is a critical step in biomarker discovery. Assessing a large number of potential protein biomarkers in a statistically significant number of samples and controls still constitutes a major technical hurdle. Multiplexed analysis offers significant advantages regarding time, reagent cost, sample requirements and the amount of data that can be generated. The two contemporary approaches in multiplexed and quantitative biomarker validation, antibody-based immunoassays and MS-based multiple (or selected) reaction monitoring, are based on different assay principles and instrument requirements. Both approaches have their own advantages and disadvantages and therefore have complementary roles in the multi-staged biomarker verification and validation process. In this review, we discuss quantitative immunoassay and multiple reaction monitoring/selected reaction monitoring assay principles and development. We also discuss choosing an appropriate platform, judging the performance of assays, obtaining reliable, quantitative results for translational research and clinical applications in the biomarker field.
KW - Biomarker
KW - Immunoassay
KW - Multiple reaction monitoring
KW - Multiplex assay
KW - Quantitation
UR - http://www.scopus.com/inward/record.url?scp=77951757994&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951757994&partnerID=8YFLogxK
U2 - 10.1002/prca.200900217
DO - 10.1002/prca.200900217
M3 - Review article
C2 - 21137048
AN - SCOPUS:77951757994
SN - 1862-8346
VL - 4
SP - 271
EP - 284
JO - Proteomics - Clinical Applications
JF - Proteomics - Clinical Applications
IS - 3
ER -